Timolol

also known as Timolol Maleate · Timoptic · Timoptol · Aquanil · Betim · Betimol · Blocadren · Fixed Dose Combination of tafluprost and timolol · +31 more

Other / unclassified targets ADRB1, ADRB2 via inhibition

Developed for: ocular hypertension · open-angle glaucoma · glaucoma · hemangioma · myopia · acne · hereditary hemorrhagic telangiectasia · angle-closure glaucoma
+16 more
· anterior ischemic optic neuropathy · benign vascular tumor · borderline glaucoma · chronic ulcer of skin · esophageal varices · exfoliation syndrome · eye disorder · low tension glaucoma · melanoma · migraine disorder · paronychia · rosacea · ulcer disease · ulcer of lower limbs · corneal edema · diabetic macular edema
Investigated by: Alcon Research · Allergan · Merck Sharp & Dohme LLC · Viatris Inc. · University of Nebraska · Auson Pharmaceuticals Inc.
+82 more
· National Eye Institute (NEI) · Pharmaceutical Research Network · Santen Inc. · Brigham and Women's Hospital · EyeD Pharma · Laboratoires Thea · Mayo Clinic · Medical University of Vienna · Santen Pharmaceutical Co., Ltd. · Sun Yat-sen University · University of California, Davis · University of Michigan · Advanced Glaucoma Specialists · Afyon Kocatepe University Hospital · Alice K. Gong · Aristotle University Of Thessaloniki · Bausch & Lomb Incorporated · Betaliq, Inc. · Canadian Glaucoma Clinical Research Council · Carmel Medical Center · Centre Hospitalier Universitaire de Nice · Centre Hospitalier Universitaire, Amiens · Chicago Center for Vision Research · Children's Hospital of Philadelphia · Credit Valley EyeCare · Federal University of São Paulo · Fondazione G.B. Bietti, IRCCS · ForSight Vision5, Inc. · Fraser Health · Glostrup University Hospital, Copenhagen · Hospices Civils de Lyon · Icahn School of Medicine at Mount Sinai · Innovative Medical · Janssen Research & Development, LLC · Jason Hsu, MD · Johns Hopkins University · Kanecia Obie Zimmerman · Keith G. LeBlanc, Jr, MD · Kukje Pharma · Laboratorios Poen · Laboratorios Sophia S.A de C.V. · Larissa University Hospital · Loyola University · Mahidol University · Maisonneuve-Rosemont Hospital · Massachusetts General Hospital · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Institutes of Health (NIH) · Ohio State University · Pfizer · Pham Ngoc Thach University of Medicine · Rady Children's Hospital, San Diego · Sant Pau Research Institute · Shahid Beheshti University of Medical Sciences · Sheba Medical Center · Society for Pediatric Dermatology · Summit Analytical LLC · Taipei Medical University WanFang Hospital · Taiwan Otsuka Pharm. Co., Ltd · Tecnoquimicas · The Emmes Company, LLC · Trial Runners, LLC · Universitaire Ziekenhuizen KU Leuven · Universiti Kebangsaan Malaysia Medical Centre · University Hospital Centre Zagreb · University of California, Los Angeles · University of California, San Diego · University of Campinas, Brazil · University of Florida · University of Kansas Medical Center · University of Medicine and Dentistry of New Jersey · University of Miami · University of Milan · University of Sao Paulo · all 88 on the full record

Regulatory milestones approvals, filings & regulatory actions · 6 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (3)	US (FDA)	BLOCADREN	—	1985-02-25 – 2009-03-13	fda.gov ↗
Label expansion	US (FDA)	TIMOLOL MALEATE	—	2007-06-08	fda.gov ↗
Approved	EU (EMA)	DuoTrav	—	2006-04-23	europa.eu ↗
Approved	US (FDA)	TIMOPTIC	—	1978-08-17	fda.gov ↗

Trials 119 · started per year

today

US approved 1978

EU approved 2006

197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 02 trials
Phase 0	NCT07474883	Mar → Aug 2026 overdue	acne	Pham Ngoc Thach University of Medicine	Recruiting	No outcome recorded
Phase 0	NCT02697318	May 2016 → Sep 2017	glaucoma	University of Waterloo	Completed	No outcome recorded
Phase 112 trials
Phase 1	NCT07036510	Jun 2025 → Jan 2027 expected	ocular hypertension, open-angle glaucoma	EyeD Pharma	Recruiting	No outcome recorded
Phase 1	NCT06941467	Jan 2025 → Apr 2026 overdue	—	Icahn School of Medicine at Mount Sinai	Recruiting	No outcome recorded
Phase 1	NCT06813807	Jun → Jul 2024	—	Auson Pharmaceuticals Inc.	Completed	No outcome recorded
Phase 1	NCT06321562	Mar 2023 → Jun 2025	open-angle glaucoma	EyeD Pharma	Terminated	No outcome recorded
Phase 1	NCT06824948	Oct → Dec 2018	—	Auson Pharmaceuticals Inc.	Completed	No outcome recorded
Phase 1	NCT02852057	Jan 2018 → Aug 2021	glaucoma	University of Florida	Completed	No outcome recorded
Phase 1	NCT02967614	Dec 2016 → Dec 2017	glaucoma, ocular hypertension	Kukje Pharma	Completed	No outcome recorded
Phase 1	NCT02774590	Mar 2016 → Mar 2021	acne, rosacea	Johns Hopkins University	Completed	No outcome recorded
Phase 1	NCT01434849	Jul 2012 → Apr 2016	hemangioma	Alice K. Gong	Terminated	No outcome recorded
Phase 1	NCT01607671	Jun 2012 → Nov 2013	anterior ischemic optic neuropathy	Fraser Health	Withdrawn	No outcome recorded
Phase 1	NCT01533376	Feb 2012 → Jan 2019	Sturge-Weber syndrome	Wills Eye	Terminated	No outcome recorded
Phase 1	NCT00879099	Apr 2009 → Jan 2010	—	Santen Inc.	Completed	No outcome recorded

Phase 1/21 trial
Phase 1/2	NCT02742649	Apr → Dec 2016	ocular hypertension, open-angle glaucoma	ForSight Vision5, Inc.	Completed	No outcome recorded
Phase 219 trials
Phase 2	NCT07384767	Jun 2026 → Sep 2027 expected	—	University of California, Davis	Not yet recruiting	No outcome recorded
Phase 2	NCT06120140	Feb 2024 → May 2027 expected	non-small cell lung carcinoma	Janssen Research & Development, LLC	Active not recruiting	No outcome recorded
Phase 2	NCT04910100	Apr 2021 → Mar 2022	ocular hypertension, open-angle glaucoma	Betaliq, Inc.	Completed	No outcome recorded
Phase 2	NCT05114239	Apr 2021 → Sep 2022	—	Keith G. LeBlanc, Jr, MD	Unknown	No outcome recorded
Phase 2	NCT04139018	Oct 2019 → May 2020	hereditary hemorrhagic telangiectasia	Washington University School of Medicine	Completed	No outcome recorded
Phase 2	NCT02913612	May 2017 → Oct 2020	hemangioma	Kanecia Obie Zimmerman	Completed	No outcome recorded
Phase 2	NCT03836664	Feb 2017 → Apr 2018	migraine disorder	University of Kansas Medical Center	Completed	No outcome recorded
Phase 2	NCT02214680	Oct 2015 → Aug 2016	—	Carmel Medical Center	Unknown	No outcome recorded
Phase 2	NCT02484716	Jun 2015 → Nov 2017	hereditary hemorrhagic telangiectasia	Hospices Civils de Lyon	Completed	No outcome recorded
Phase 2	NCT02422017	Apr 2015 → May 2016	ulcer of lower limbs	Centre Hospitalier Universitaire, Amiens	Completed	No outcome recorded
Phase 2	NCT02145884	May 2014 → Oct 2016	hemangioma	Rady Children's Hospital, San Diego	Completed	No outcome recorded
Phase 2	NCT02731287	Mar 2014 → Jan 2017	hemangioma	Sant Pau Research Institute	Completed	No outcome recorded
Phase 2	NCT01408056	Feb 2011 → Jan 2014	hemangioma	Children's Hospital of Philadelphia	Withdrawn	No outcome recorded
Phase 2	NCT00832377	Apr 2009 → Mar 2010	glaucoma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT00572936	Mar 2006 → Nov 2009	glaucoma	University of Nebraska	Completed	No outcome recorded
Phase 2	NCT00287521	Nov 2005 → Feb 2006	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 2	NCT00368602	Jun 2005 → Jun 2007	ulcer disease	University of California, Davis	Terminated	No outcome recorded
Phase 2	NCT00579969	Dec 2003 → Oct 2008	glaucoma	University of Nebraska	Terminated	No outcome recorded
Phase 2	NCT00317577	Dec 1998 → May 2004	open-angle glaucoma	Chicago Center for Vision Research	Completed	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT06677853	Oct 2020 → Jun 2022	hemangioma	Auson Pharmaceuticals Inc.	Completed	No outcome recorded
Phase 2/3	NCT03579160	Jan 2019 → Jan 2022	—	Brigham and Women's Hospital	Terminated	No outcome recorded
Phase 2/3	NCT03452072	Aug 2018 → Dec 2020	—	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 330 trials
Phase 3	NCT05503901	Aug 2022 → Jan 2024	open-angle glaucoma	Santen Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT04898387	Mar 2021 → Apr 2023	ocular hypertension	Laboratoires Thea	Completed	No outcome recorded
Phase 3	NCT03822559	Jan 2019 → Apr 2023	open-angle glaucoma	Santen Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT03282981	Jul 2018 → Dec 2023	chronic ulcer of skin	VA Office of Research and Development	Completed	No outcome recorded
Phase 3	NCT02390284	Sep 2015 → Oct 2024	glaucoma	University of Miami	Terminated	No outcome recorded
Phase 3	NCT02247804	Dec 2014 → Feb 2018	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 3	NCT02250651	Dec 2014 → Oct 2018	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 3	NCT01284166	Jul 2013 → May 2014	glaucoma, ocular hypertension	Allergan	Withdrawn	No outcome recorded
Phase 3	NCT01685398	Sep 2012 → Mar 2023	hemangioma	Mahidol University	Completed	No outcome recorded
Phase 3	NCT01746602	Jul 2011 → Sep 2012	—	Medical University of Vienna	Terminated	No outcome recorded
Phase 3	NCT01306461	Mar 2011 → Apr 2012	ocular hypertension, open-angle glaucoma	Santen Inc.	Completed	No outcome recorded
Phase 3	NCT01272609	Feb 2011 → Sep 2012	melanoma	Centre Hospitalier Universitaire de Nice	Terminated	No outcome recorded
Phase 3	NCT01292460	Feb 2011 → Sep 2012	ocular hypertension, open-angle glaucoma	Santen Inc.	Completed	No outcome recorded
Phase 3	NCT00465803	Mar 2007 → Jan 2009	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00383019	Nov 2006 → Oct 2007	glaucoma, ocular hypertension	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00546286	May 2006 → Aug 2007	ocular hypertension, open-angle glaucoma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00277498	Dec 2005 → Jun 2007	ocular hypertension, open-angle glaucoma	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00314158	Nov 2005 → Jan 2007	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00230763	Sep 2005 → Oct 2007	ocular hypertension, open-angle glaucoma	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00159653	Jul 2005 → Jun 2007	ocular hypertension, open-angle glaucoma	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00219596	Jun 2005 → Sep 2006	ocular hypertension, open-angle glaucoma	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00108017	Apr 2005 → Jul 2006	glaucoma, ocular hypertension	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00332059	May 2003 → Sep 2004	ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT00061542	Jan 2003 → Nov 2006	glaucoma, ocular hypertension	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00332540	Aug 2001 → Aug 2003	ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT00332072	Aug 2001 → Aug 2003	ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT00051155	Jan 2001 → Jul 2004	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00800267	Jul 1997 → Jun 1999	glaucoma, ocular hypertension	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00006398	Aug 1993 → Sep 2002	cirrhosis of liver, esophageal varices, portal hypertension	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 3	NCT02154217	? → Dec 2004	glaucoma	University of Milan	Completed	No outcome recorded

Phase 439 trials
Phase 4	NCT07690397	Jun 2026 → Jul 2027 expected	ocular hypertension, open-angle glaucoma	Tecnoquimicas	Active not recruiting	No outcome recorded
Phase 4	NCT05857267	Mar 2023 → Nov 2024	ocular hypertension, open-angle glaucoma	Laboratorios Poen	Completed	No outcome recorded
Phase 4	NCT04702789	Oct 2021 → Nov 2023	ocular hypertension, open-angle glaucoma	Laboratorios Sophia S.A de C.V.	Terminated	No outcome recorded
Phase 4	NCT06761313	Mar 2021 → Dec 2024 overdue	glaucoma	Federal University of São Paulo	Active not recruiting	No outcome recorded
Phase 4	NCT04412096	Nov 2020 → May 2025	glaucoma, ocular hypertension	Ohio State University	Completed	No outcome recorded
Phase 4	NCT05299593	Jun 2020 → Jun 2022	ocular hypertension, open-angle glaucoma	Fondazione G.B. Bietti, IRCCS	Unknown	No outcome recorded
Phase 4	NCT04098861	Jan 2019 → Aug 2020	open-angle glaucoma	Universiti Kebangsaan Malaysia Medical Centre	Unknown	No outcome recorded
Phase 4	NCT02863705	Jul 2016 → Jul 2018	low tension glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT02571712	Nov 2015 → Jun 2018	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT02053298	Jan 2014 → Dec 2015	open-angle glaucoma	Universitaire Ziekenhuizen KU Leuven	Completed	No outcome recorded
Phase 4	NCT03966560	Jan 2014 → Jan 2015	open-angle glaucoma	Afyon Kocatepe University Hospital	Completed	No outcome recorded
Phase 4	NCT02003391	Dec 2013 → May 2015	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT01677507	Aug 2012 → Aug 2016	glaucoma	University of Michigan	Completed	No outcome recorded
Phase 4	NCT01535768	Feb 2012 → Jun 2018	glaucoma	Credit Valley EyeCare	Unknown	No outcome recorded
Phase 4	NCT01518244	Dec 2011 → Feb 2013	glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT01978015	Oct 2011 → Jul 2012	anterior uveitis, cystoid macular edema	University of Campinas, Brazil	Completed	No outcome recorded
Phase 4	NCT01484951	May 2011 → Mar 2012	glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT01263444	Mar 2011 → Apr 2013	glaucoma, ocular hypertension	Alcon Research	Completed	No outcome recorded
Phase 4	NCT01230736	Oct 2010 → Feb 2011	glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT01159756	Jul 2010 → Nov 2011	ocular hypertension	Alcon Research	Completed	No outcome recorded
Phase 4	NCT01250457	Jun 2010 → Jul 2012	benign vascular tumor	Loyola University	Withdrawn	No outcome recorded
Phase 4	NCT01055366	Mar 2010 → Dec 2011	open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT01151904	Nov 2009 → Feb 2012	angle-closure glaucoma	Allergan	Terminated	No outcome recorded
Phase 4	NCT00972426	Oct 2009 → Aug 2010	glaucoma	Taiwan Otsuka Pharm. Co., Ltd	Completed	No outcome recorded
Phase 4	NCT00906087	Aug 2009 → Jul 2012	glaucoma	University of Michigan	Completed	No outcome recorded
Phase 4	NCT00941096	Jul 2009 → Nov 2010	glaucoma, ocular hypertension	Larissa University Hospital	Completed	No outcome recorded
Phase 4	NCT00957190	May 2009 → Sep 2011	eye disorder	Maisonneuve-Rosemont Hospital	Completed	No outcome recorded
Phase 4	NCT00869141	Mar 2009 → Mar 2013	glaucoma	University of California, Los Angeles	Completed	No outcome recorded
Phase 4	NCT00759239	Sep 2008 → Jan 2011	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT01155219	Jul 2008 → Jul 2009	glaucoma	Laboratoires Thea	Completed	No outcome recorded
Phase 4	NCT00508469	Oct 2007 → Jan 2010	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT00519753	Aug 2007 → Dec 2008	glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT00545064	May 2007 → Sep 2008	ocular hypertension, open-angle glaucoma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 4	NCT00330577	Apr 2006 → Apr 2007	ocular hypertension, open-angle glaucoma	Aristotle University Of Thessaloniki	Completed	No outcome recorded
Phase 4	NCT00273455	Jan 2006 → May 2007	open-angle glaucoma	Pharmaceutical Research Network	Completed	No outcome recorded
Phase 4	NCT00273442	Nov 2005 → Apr 2007	exfoliation syndrome, ocular hypertension, open-angle glaucoma	Pharmaceutical Research Network	Completed	No outcome recorded
Phase 4	NCT00273429	Apr → Dec 2005	ocular hypertension, open-angle glaucoma	Pharmaceutical Research Network	Completed	No outcome recorded
Phase 4	NCT00143208	May 2003 → Apr 2006	glaucoma, ocular hypertension	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00348023	—	glaucoma	Innovative Medical	Completed	No outcome recorded

Phase not applicable13 trials
—	NCT05850936	Jun 2023 → Nov 2026 expected	myopia	Sun Yat-sen University	Active not recruiting	No outcome recorded
—	NCT05165082	Dec 2021 → Jan 2023	paronychia	Taipei Medical University WanFang Hospital	Completed	No outcome recorded
—	NCT04891588	Mar → Sep 2021	ocular hypertension, open-angle glaucoma	University Hospital Centre Zagreb	Unknown	No outcome recorded
—	NCT04296916	Apr 2020 → Oct 2024	borderline glaucoma, myopia	Sun Yat-sen University	Unknown	No outcome recorded
—	NCT03931317	Dec 2018 → May 2021	ocular hypertension, open-angle glaucoma	University of California, San Diego	Completed	No outcome recorded
—	NCT03220490	Nov 2017 → Nov 2022	glaucoma	Sheba Medical Center	Unknown	No outcome recorded
—	NCT02522039	May → Nov 2014	glaucoma	Glostrup University Hospital, Copenhagen	Completed	No outcome recorded
—	NCT01843920	Jun 2011 → Apr 2013	—	Jason Hsu, MD	Completed	No outcome recorded
—	NCT01873131	Feb 2011 → Dec 2025 overdue	hemangioma	Massachusetts General Hospital	Recruiting	No outcome recorded
—	NCT01506635	Mar → Dec 2010	myopia	Shahid Beheshti University of Medical Sciences	Completed	No outcome recorded
—	NCT00275756	Sep 2008 → Nov 2014	glaucoma	Medical University of Vienna	Withdrawn	No outcome recorded
—	NCT00440336	Oct 2006 → ?	open-angle glaucoma	Advanced Glaucoma Specialists	Unknown	No outcome recorded
—	NCT00435058	Sep 2005 → Apr 2006	glaucoma	University of Sao Paulo	Completed	No outcome recorded

Also used as a comparator or background therapy in 131 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT01147601 Comparator	Mar 2010 → Oct 2012	hemangioma	Oregon Health and Science University	Terminated	No outcome recorded
Phase 13 trials
Phase 1	NCT01845038 Comparator	Apr 2013 → Mar 2014	glaucoma	Ocular Therapeutix, Inc.	Completed	No outcome recorded
Phase 1	NCT01434888 Comparator	Sep → Dec 2011	—	Santen Inc.	Completed	No outcome recorded
Phase 1	NCT01215786 Comparator	Oct → Dec 2010	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 1/26 trials
Phase 1/2	NCT06120842 Comparator	Oct 2023 → Jan 2025 overdue	cataract, glaucoma, ocular hypertension	SpyGlass Pharma, Inc.	Active not recruiting	No outcome recorded
Phase 1/2	NCT04149899 Comparator	Nov 2019 → Jan 2021	ocular hypertension, open-angle glaucoma	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 1/2	NCT01752049 Comparator	May 2013 → Aug 2019	hereditary hemorrhagic telangiectasia	Unity Health Toronto	Completed	No outcome recorded
Phase 1/2	NCT01520116 Comparator	Jan → Dec 2012	ocular hypertension, open-angle glaucoma	Altheos, Inc.	Unknown	No outcome recorded
Phase 1/2	NCT01279083 Comparator	Jan → Nov 2011	ocular hypertension, open-angle glaucoma	Santen Inc.	Completed	No outcome recorded
Phase 1/2	NCT00753168 Comparator	Sep → Dec 2008	ocular hypertension, open-angle glaucoma	Othera Pharmaceuticals	Completed	No outcome recorded

Phase 220 trials
Phase 2	NCT07583862 Comparator	Jul 2026 → Jul 2028 expected	—	Geisinger Clinic	Not yet recruiting	No outcome recorded
Phase 2	NCT07168902 Comparator	Oct 2025 → May 2026 overdue	glaucoma	Bausch & Lomb Incorporated	Active not recruiting	No outcome recorded
Phase 2	NCT06030193 Comparator	Aug 2025 → Feb 2026	low tension glaucoma	Qlaris Bio, Inc.	Completed	No outcome recorded
Phase 2	NCT06152861 Comparator	Nov 2023 → Aug 2024	ocular hypertension, open-angle glaucoma	Glaukos Corporation	Unknown	No outcome recorded
Phase 2	NCT05913232 Comparator	Aug 2023 → Aug 2024	ocular hypertension, open-angle glaucoma	D. Western Therapeutics Institute, Inc.	Completed	No outcome recorded
Phase 2	NCT04857827 Comparator	Sep 2021 → Aug 2022	low tension glaucoma	Qlaris Bio, Inc.	Completed	No outcome recorded
Phase 2	NCT04830397 Comparator	Mar 2021 → Feb 2022	ocular hypertension, open-angle glaucoma	Qlaris Bio, Inc.	Completed	No outcome recorded
Phase 2	NCT04742283 Comparator	Dec 2020 → Dec 2021	ocular hypertension, open-angle glaucoma	Santen Inc.	Completed	No outcome recorded
Phase 2	NCT02754596 Comparator	Mar 2016 → Aug 2017	open-angle glaucoma	Glaukos Corporation	Completed	No outcome recorded
Phase 2	NCT02358369 Comparator	Jan → Aug 2015	ocular hypertension, open-angle glaucoma	ForSight Vision5, Inc.	Completed	No outcome recorded
Phase 2	NCT02312544 Comparator	Nov 2014 → Sep 2015	glaucoma, ocular hypertension	Ocular Therapeutix, Inc.	Completed	No outcome recorded
Phase 2	NCT02250612 Comparator	Oct 2014 → Aug 2015	ocular hypertension, open-angle glaucoma	Sylentis, S.A.	Completed	No outcome recorded
Phase 2	NCT01915940 Comparator	Oct 2013 → Sep 2014	ocular hypertension, open-angle glaucoma	ForSight Vision5, Inc.	Completed	No outcome recorded
Phase 2	NCT01917383 Comparator	Aug 2013 → Aug 2014	ocular hypertension, open-angle glaucoma	Inotek Pharmaceuticals Corporation	Completed	No outcome recorded
Phase 2	NCT01707381 Comparator	Nov 2012 → Dec 2013	ocular hypertension, open-angle glaucoma	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 2	NCT01699464 Comparator	Oct 2012 → Apr 2013	ocular hypertension, open-angle glaucoma	Aerie Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01302249 Comparator	Feb → Dec 2011	glaucoma, ocular hypertension	Aerie Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01887223 Comparator	May 2010 → Jun 2011	open-angle glaucoma	University of Sao Paulo General Hospital	Completed	No outcome recorded
Phase 2	NCT00620256 Comparator	Nov 2007 → Jul 2008	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 2	NCT01062971 Comparator	Feb 2006 → Aug 2007	ocular hypertension, open-angle glaucoma	Laboratorios Sophia S.A de C.V.	Completed	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT07075718 Comparator	Jun 2025 → Mar 2028 expected	glaucoma	Glaukos Corporation	Recruiting	No outcome recorded
Phase 2/3	NCT05083689 Comparator	Oct 2021 → Mar 2022	diabetic macular edema	Shahid Beheshti University of Medical Sciences	Unknown	No outcome recorded
Phase 2/3	NCT00991822 Comparator	May 1999 → Dec 2001	open-angle glaucoma	Medical University of Vienna	Completed	No outcome recorded
Phase 351 trials
Phase 3	NCT07495852 Comparator	Feb 2026 → Jun 2028 expected	glaucoma	Glaukos Corporation	Recruiting	No outcome recorded
Phase 3	NCT07218796 Comparator	Oct 2025 → May 2029 expected	cataract, glaucoma, ocular hypertension	SpyGlass Pharma, Inc.	Recruiting	No outcome recorded
Phase 3	NCT07218783 Comparator	Oct 2025 → Mar 2029 expected	cataract, ocular hypertension, open-angle glaucoma	SpyGlass Pharma, Inc.	Recruiting	No outcome recorded
Phase 3	NCT06643416 Comparator	Oct 2024 → Dec 2025 overdue	paronychia	Queen Mary Hospital, Hong Kong	Recruiting	No outcome recorded
Phase 3	NCT06140186 Comparator	Apr → Dec 2023	paronychia	Queen Mary Hospital, Hong Kong	Unknown	No outcome recorded
Phase 3	NCT03691662 Comparator	Sep 2018 → Oct 2019	glaucoma	Santen Inc.	Completed	No outcome recorded
Phase 3	NCT03868124 Comparator	Sep 2018 → Jun 2022	ocular hypertension, open-angle glaucoma	Glaukos Corporation	Completed	No outcome recorded
Phase 3	NCT03691649 Comparator	Sep 2018 → Dec 2019	glaucoma	Santen Inc.	Completed	No outcome recorded
Phase 3	NCT03519386 Comparator	Jul 2018 → Apr 2022	ocular hypertension, open-angle glaucoma	Glaukos Corporation	Completed	No outcome recorded
Phase 3	NCT03284853 Comparator	Sep 2017 → Nov 2020	ocular hypertension, open-angle glaucoma	Aerie Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02822729 Background	Jul 2016 → Nov 2017	ocular hypertension, open-angle glaucoma	Santen Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT02558374 Comparator	Sep 2015 → Dec 2016	ocular hypertension, open-angle glaucoma	Aerie Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02565173 Comparator	Sep 2015 → Nov 2016	ocular hypertension, open-angle glaucoma	Inotek Pharmaceuticals Corporation	Completed	No outcome recorded
Phase 3	NCT02278614 Comparator	Dec 2014 → Nov 2015	ocular hypertension, open-angle glaucoma	Laboratoires Thea	Completed	No outcome recorded
Phase 3	NCT02246764 Comparator	Sep 2014 → Dec 2016	glaucoma, ocular hypertension	Aerie Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02207621 Comparator	Jul 2014 → Mar 2016	ocular hypertension, open-angle glaucoma	Aerie Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02207491 Comparator	Jul 2014 → Mar 2015	ocular hypertension, open-angle glaucoma	Aerie Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01749904 Comparator	Jan 2013 → Jun 2015	ocular hypertension, open-angle glaucoma	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 3	NCT01749930 Comparator	Jan 2013 → May 2015	ocular hypertension, open-angle glaucoma	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 3	NCT01652664 Comparator	Sep 2012 → Mar 2014	glaucoma, ocular hypertension	Alcon Research	Completed	No outcome recorded
Phase 3	NCT01254604 Comparator	Dec 2011 → May 2013	ocular hypertension, open-angle glaucoma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT01426113 Comparator	Sep 2011 → Oct 2014	glaucoma	Allergan	Terminated	No outcome recorded
Phase 3	NCT01342081 Comparator	May 2011 → Sep 2012	ocular hypertension, open-angle glaucoma	Santen Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT01342094 Comparator	May 2011 → Sep 2012	ocular hypertension, open-angle glaucoma	Santen Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT01241240 Comparator	Mar 2011 → Sep 2013	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 3	NCT01217606 Comparator	Jan 2011 → Sep 2014	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 3	NCT01357616 Comparator	Nov 2010 → Jan 2013	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT01216943 Background	Nov 2010 → Aug 2012	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT01177098 Comparator	Oct 2010 → Feb 2012	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT01168414 Background	Aug 2010 → Jan 2011	ocular hypertension, open-angle glaucoma	Ministry of Health, Malaysia	Completed	No outcome recorded
Phase 3	NCT00912054 Background	Mar 2010 → May 2011	ocular hypertension, open-angle glaucoma	Alcon Research	Terminated	No outcome recorded
Phase 3	NCT01026831 Comparator	Jan → Sep 2010	ocular hypertension, open-angle glaucoma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00872651 Comparator	Jan 2010 → Nov 2011	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT01004900 Comparator	Jun 2009 → Mar 2011	glaucoma	Singapore Eye Research Institute	Unknown	No outcome recorded
Phase 3	NCT00800423 Comparator	Jan 2009 → Jan 2010	corneal edema	Rabin Medical Center	Unknown	No outcome recorded
Phase 3	NCT00716859 Comparator	Jul 2008 → Nov 2009	glaucoma	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00672997 Background	May → Dec 2008	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00576342 Background	Dec 2007 → Jan 2008	glaucoma, ocular hypertension	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00980473 Comparator	Sep 2007 → Sep 2011	glaucoma	Singapore National Eye Centre	Unknown	No outcome recorded
Phase 3	NCT00449956 Comparator	Mar 2007 → Feb 2008	glaucoma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00333125 Comparator	Apr 2006 → Feb 2007	glaucoma, ocular hypertension	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00651612 Comparator	Nov 2005 → Jan 2007	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT00314171 Comparator	Oct 2005 → Aug 2007	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00293800 Comparator	Jul 2004 → Dec 2005	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00293787 Comparator	Jun 2004 → Aug 2005	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00652106 Comparator	Jun 2003 → Mar 2004	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT00311389 Comparator	Jan 2003 → Sep 2004	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00856622 Comparator	Aug 1997 → Jun 1999	ocular hypertension, open-angle glaucoma	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00751127 Comparator	Jan 1993 → Feb 1994	ocular hypertension, open-angle glaucoma	Pfizer	Completed	No outcome recorded
Phase 3	NCT00751049 Comparator	Dec 1992 → Dec 1993	ocular hypertension, open-angle glaucoma	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00751062 Comparator	Nov 1992 → Dec 1993	ocular hypertension, open-angle glaucoma	Viatris Inc.	Completed	No outcome recorded

Phase 437 trials
Phase 4	NCT06883123 Comparator	May 2025 → Apr 2026 overdue	open-angle glaucoma	Prairie Eye Center	Recruiting	No outcome recorded
Phase 4	NCT06369077 Comparator	Apr → Jul 2024	open-angle glaucoma	CT Glaucoma Associates	Terminated	No outcome recorded
Phase 4	NCT05479123 Comparator	Jun 2022 → Mar 2025	hemangioma	The University of Texas Health Science Center, Houston	Terminated	No outcome recorded
Phase 4	NCT06078592 Comparator	Oct 2021 → Dec 2022	glaucoma, ocular hypertension	CHA University	Completed	No outcome recorded
Phase 4	NCT04288700 Comparator	Oct 2019 → Dec 2020	hemangioma	Ain Shams University	Unknown	No outcome recorded
Phase 4	NCT03648229 Comparator	Sep 2019 → Jun 2022	open-angle glaucoma	West Virginia University	Withdrawn	No outcome recorded
Phase 4	NCT03323164 Comparator	Jul 2017 → Dec 2018	low tension glaucoma	Wills Eye	Completed	No outcome recorded
Phase 4	NCT02730871 Background	Jun 2016 → Jul 2018	ocular hypertension, open-angle glaucoma	Alcon Research	Terminated	No outcome recorded
Phase 4	NCT02802137 Comparator	Mar → Dec 2015	eye adnexa disorder, open-angle glaucoma	Aristotle University Of Thessaloniki	Completed	No outcome recorded
Phase 4	NCT02325518 Background	Dec 2014 → Dec 2015	ocular hypertension, open-angle glaucoma	Alcon, a Novartis Company	Completed	No outcome recorded
Phase 4	NCT01927406 Background	Jun 2014 → Dec 2016	endocrine exophthalmos, glaucoma, ocular hypertension	Stanford University	Withdrawn	No outcome recorded
Phase 4	NCT02097719 Comparator	May → Dec 2014	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT01978600 Comparator	Oct 2013 → Mar 2014	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT01881126 Comparator	Jun 2013 → Oct 2014	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT01547598 Comparator	Dec 2011 → Jul 2013	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT01340014 Background	Sep 2011 → Oct 2012	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT01446497 Comparator	Oct 2010 → Aug 2011	low tension glaucoma	Seoul National University Hospital	Unknown	No outcome recorded
Phase 4	NCT01243567 Comparator	Jun 2010 → Feb 2012	open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT01111890 Background	Apr 2010 → Jul 2011	glaucoma, ocular hypertension	Alcon Research	Completed	No outcome recorded
Phase 4	NCT01448837 Comparator	Apr 2010 → Mar 2011	glaucoma	Aristotle University Of Thessaloniki	Completed	No outcome recorded
Phase 4	NCT01170884 Comparator	Dec 2009 → Sep 2010	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT00800540 Background	Feb 2009 → Jan 2012	open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT00887029 Comparator	Jan → Nov 2009	ocular hypertension, open-angle glaucoma	Ophthalmic Consultants Centres, Canada	Completed	No outcome recorded
Phase 4	NCT00972257 Comparator	Jan → Sep 2009	open-angle glaucoma	Aristotle University Of Thessaloniki	Completed	No outcome recorded
Phase 4	NCT00811850 Comparator	Dec 2008 → Dec 2009	glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT00811564 Comparator	Dec 2008 → Jan 2010	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT00804648 Comparator	Nov → Dec 2008	ocular hypertension, open-angle glaucoma	Vistakon Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00735449 Comparator	Jul 2008 → Dec 2009	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT00698945 Comparator	Jun → Nov 2008	ocular hypertension, open-angle glaucoma	Bp Consulting, Inc	Completed	No outcome recorded
Phase 4	NCT00757835 Comparator	May 2008 → Mar 2009	glaucoma	Aristotle University Of Thessaloniki	Completed	No outcome recorded
Phase 4	NCT00471068 Comparator	Mar 2007 → Aug 2008	ocular hypertension, open-angle glaucoma	Alcon Research	Terminated	No outcome recorded
Phase 4	NCT00444184 Comparator	Mar 2007 → Jan 2008	glaucoma	Aristotle University Of Thessaloniki	Completed	No outcome recorded
Phase 4	NCT00471380 Comparator	Mar 2007 → Oct 2008	glaucoma, ocular hypertension	Alcon Research	Completed	No outcome recorded
Phase 4	NCT00763061 Comparator	May 2006 → Apr 2008	glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT00273481 Background	Sep 2005 → Apr 2007	ocular hypertension, open-angle glaucoma	Pharmaceutical Research Network	Completed	No outcome recorded
Phase 4	NCT00140049 Background	Jul 2005 → Jul 2006	ocular hypertension, open-angle glaucoma	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT01655758 Comparator	Jan 2002 → Dec 2003	ocular hypertension	University of Parma	Completed	No outcome recorded

Phase not applicable10 trials
—	NCT07168395 Comparator	Oct 2026 → Nov 2027 expected	—	University of California, Los Angeles	Not yet recruiting	No outcome recorded
—	NCT04868175 Comparator	Oct 2019 → Mar 2021	glaucoma	The University of Hong Kong	Completed	No outcome recorded
—	NCT02630719 Comparator	Jan 2016 → Aug 2017	migraine disorder	University of Missouri, Kansas City	Terminated	No outcome recorded
—	NCT02140450 Comparator	Feb 2012 → Jan 2014	—	Mashhad University of Medical Sciences	Completed	No outcome recorded
—	NCT01229462 Comparator	Oct 2010 → Sep 2011	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
—	NCT01068964 Comparator	Feb → Sep 2010	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
—	NCT00824824 Comparator	Jan 2009 → Aug 2012	glaucoma	Massachusetts Eye and Ear Infirmary	Completed	No outcome recorded
—	NCT00815373 Comparator	Dec 2008 → Dec 2011	ocular hypertension, open-angle glaucoma	Meir Medical Center	Withdrawn	No outcome recorded
—	NCT00684489 Comparator	Sep 2003 → Mar 2005	essential hypertension	Medical University of South Carolina	Completed	No outcome recorded
—	NCT00804115 Comparator	Aug 2000 → Sep 2007	exfoliation syndrome, ocular hypertension	The New York Eye & Ear Infirmary	Unknown	No outcome recorded

Evidence & citations 45 cited values

Every value below carries the sentence it was read from. 258 sources stand behind the page.

Field	Value	Cited text
Known as	timolol	“To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure...” NCT00159653 ↗ 220 “From D1 to D10, each subject will receive one drop of 0.5% timolol maleate ophthalmic gel forming solution each in the left and right eyes once daily at the same time every day...” NCT06813807 ↗ “The goal of this clinical trial is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma or ocular hypertension and...” NCT07036510 ↗ “Travacom(R) is a combination topical ocular agent, containing travoprost and timolol, which lower intraocular pressure (IOP) by complementary mechanisms of action.” NCT01159756 ↗ “The purpose of this study is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma and pseudophakia” NCT06321562 ↗ “This study is designed as an open label evaluation of the efficacy of latanoprost and timolol fixed combination (Xalacom) after 6 month of treatment.” NCT00143208 ↗ “effects on tear film thickness of timolol with preservatives (Timoptic 0.5%) will be compared to timolol without preservatives (Timophtal sine 0.5%).” NCT01746602 ↗ “OBJECTIVE: To assess the efficacy and safety of fixed-combination latanoprost-timolol (FCLT) vs latanoprost or timolol monotherapy.” PMID 20142538 ↗ Feb 2010 “IOP-lowering eye drops Xalacom eyedrops (combination drops, fixed latanoprost with timolol) will be the choice for treatment.” NCT05850936 ↗ “The Fixed Combination Of Latanoprost And Timolol (Xalacom) With The Fixed Combination Of Dorzolamide And Timolol (Cosopt)” NCT00140049 ↗ “Fixed combination of Bimatoprost and Timolol (BTFC; Ganfort (300 microgram + 5 mg/ml eyedrops solution)” NCT01168414 ↗ “a beta blocker eye drop (timolol 0.25% 1 gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID)” NCT01535768 ↗ “GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.” NCT03284853 ↗ “travoprost APS 40 micrograms/ml / timolol 5 mg/ml, Eye Drops, Solution, once daily” NCT00912054 ↗ “T2347: fixed combination Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops” NCT02278614 ↗ “Brimonidine tartrate 2.0mg, Timolol maleate 6.8mg(without preservative)” NCT06078592 ↗ “latanoprost 0.005% adn timolol 0.5%, one drop, once daily” NCT00383019 ↗ “Geltim LP® 1 mg/g (0.1% unpreserved timolol maleate gel)” NCT01155219 ↗ “propranolol, timolol, acebutolol, penbutolol pindolol” NCT00684489 ↗ “These may include propranolol, nadolol, and timolol.” NCT07168395 ↗ “Timolol Maleate Ophthalmic Solution, 0.5% (timolol)” NCT03519386 ↗ “timolol 0.5% will be added as second medication.” NCT04296916 ↗ “dorzolamide hydrochloride and timolol maleate” NCT06883123 ↗ “Timolol Maleate ophthalmic solution, 0.5%” NCT03868124 ↗ “Timolol Ocular Insert” NCT02742649 ↗ “Brimonidine , Timolol” NCT02967614 ↗ “timolol” NCT01873131 ↗ NCT01254604 ↗ NCT01434888 ↗ NCT01068964 ↗ NCT00546286 ↗ NCT02730871 ↗ NCT01426113 ↗ NCT05114239 ↗ NCT05913232 ↗ NCT00311389 ↗ NCT01279083 ↗ NCT01699464 ↗ NCT01881126 ↗ NCT01215786 ↗ NCT00763061 ↗ NCT03282981 ↗ NCT00471380 ↗ NCT01284166 ↗ NCT00651612 ↗ NCT00293787 ↗ NCT05083689 ↗ NCT04139018 ↗ NCT04891588 ↗ NCT00314158 ↗ NCT00314171 ↗ NCT01927406 ↗ NCT00824824 ↗ NCT02247804 ↗ NCT00051155 ↗ NCT01506635 ↗ NCT02422017 ↗ NCT01306461 ↗ NCT00906087 ↗ NCT06120140 ↗ NCT00317577 ↗ NCT06120842 ↗ NCT07384767 ↗ NCT00872651 ↗ NCT01216943 ↗ NCT00991822 ↗ NCT02571712 ↗ NCT02145884 ↗ NCT00108017 ↗ NCT01263444 ↗ NCT00006398 ↗ NCT07218783 ↗ NCT07218796 ↗ NCT02630719 ↗ NCT03579160 ↗ NCT01446497 ↗ NCT00572936 ↗ NCT01655758 ↗ NCT00735449 ↗ NCT02207621 ↗ NCT00545064 ↗ NCT05299593 ↗ NCT03452072 ↗ NCT04868175 ↗ NCT00293800 ↗ NCT01917383 ↗ NCT05503901 ↗ NCT01342081 ↗ NCT00275756 ↗ NCT04412096 ↗ NCT02731287 ↗ NCT07495852 ↗ NCT02822729 ↗ NCT01915940 ↗ NCT04742283 ↗ NCT01533376 ↗ NCT00230763 ↗ NCT00435058 ↗ NCT01241240 ↗ NCT01055366 ↗ NCT01342094 ↗ NCT01677507 ↗ NCT00672997 ↗ NCT04288700 ↗ NCT02312544 ↗ NCT02484716 ↗ NCT06152861 ↗ NCT07690397 ↗ NCT00508469 ↗ NCT01357616 ↗ NCT01217606 ↗ NCT00576342 ↗ NCT02053298 ↗ NCT04910100 ↗ NCT02390284 ↗ NCT03836664 ↗ NCT01170884 ↗ NCT02852057 ↗ NCT01151904 ↗ NCT02325518 ↗ NCT01026831 ↗ NCT00800540 ↗ NCT00804648 ↗ NCT00620256 ↗ NCT03966560 ↗ NCT01408056 ↗ NCT00219596 ↗ NCT02754596 ↗ NCT00980473 ↗ NCT01250457 ↗ NCT06643416 ↗ NCT07075718 ↗ NCT04857827 ↗ NCT03220490 ↗ NCT04098861 ↗ NCT01652664 ↗ NCT03822559 ↗ NCT01230736 ↗ NCT04898387 ↗ NCT07583862 ↗ NCT02522039 ↗ NCT01292460 ↗ NCT00887029 ↗ NCT00273455 ↗ NCT00273442 ↗ NCT00757835 ↗ NCT01340014 ↗ NCT00348023 ↗ NCT02154217 ↗ NCT00273429 ↗ NCT01229462 ↗ NCT02913612 ↗ NCT00751049 ↗ NCT02140450 ↗ NCT00751062 ↗ NCT00751127 ↗ NCT00832377 ↗ NCT01749930 ↗ NCT01749904 ↗ NCT05165082 ↗ NCT06030193 ↗ NCT02214680 ↗ NCT02358369 ↗ NCT01448837 ↗ NCT00941096 ↗ NCT00652106 ↗ NCT07474883 ↗ NCT00972426 ↗ NCT02774590 ↗ NCT00330577 ↗ NCT02558374 ↗ NCT00957190 ↗ NCT01607671 ↗ NCT00800267 ↗ NCT00972257 ↗ NCT00332059 ↗ NCT04149899 ↗ NCT02003391 ↗ NCT01873131 ↗ NCT01685398 ↗ NCT00716859 ↗ NCT05479123 ↗ NCT00800423 ↗ NCT02697318 ↗ NCT01272609 ↗ NCT00332072 ↗ NCT01147601 ↗ NCT00759239 ↗ NCT07168902 ↗ NCT00856622 ↗ NCT00449956 ↗ NCT00061542 ↗ NCT06941467 ↗ NCT03648229 ↗ NCT00579969 ↗ NCT01243567 ↗ NCT06369077 ↗ NCT02802137 ↗ NCT00869141 ↗ NCT04702789 ↗ NCT00332540 ↗ NCT00444184 ↗ NCT02250651 ↗ NCT00811850 ↗ NCT01843920 ↗ NCT01111890 ↗ NCT00811564 ↗ NCT01004900 ↗ NCT02097719 ↗ NCT00333125 ↗ NCT01177098 ↗ NCT01547598 ↗ NCT00753168 ↗ NCT05857267 ↗ NCT00465803 ↗ NCT00804115 ↗ NCT01302249 ↗ NCT01484951 ↗ NCT02565173 ↗ NCT01845038 ↗ NCT01062971 ↗
Known as	Aquanil	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Betim	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Betimol	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Blocadren	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Fixed Dose Combination of tafluprost and timolol	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01306461 ↗
Known as	Geltim LP	“Geltim LP® 1 mg/g (0.1% unpreserved timolol maleate gel)” NCT01155219 ↗
Known as	Glau-opt	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Glaucol	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Istalol	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00698945 ↗
Known as	NSC-757351	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Nyogel	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Ophtamolol	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	TGFS	“Timolol Gel-forming Solution (TGFS)” NCT00061542 ↗
Known as	Tiloptic	“first "Brimonidine", "Alphagan®" (an alpha-agonist) followed by "Timolol", "Tiloptic®" (a beta-blocker).” NCT03220490 ↗
Known as	TIM	“A total of 189 prior timolol users were randomized within the timolol stratum (TS) to receive either FC (n = 95) or timolol 0.5% (TIM; n = 94).” PMID 25447269 ↗ Dec 2014
Known as	Timolol (as maleate)	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Timolol anhydrous	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Timolol Gel-forming Solution (TGFS)	“Timolol Gel-forming Solution (TGFS)” NCT00061542 ↗
Known as	Timolol hemihydrate	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Timolol hydrogen maleate salt	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	timolol malate	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02863705 ↗
Known as	Timolol Maleate	“The combination of the eye drops Bimatoprost 0.3%, Timolol Maleate 0.5%, and Brimonidine Tartrate 0.2% in separate vials is traditionally used in patients with difficult...” NCT06761313 ↗ 45 “PURPOSE: To compare the diurnal intraocular pressure (IOP)-lowering effect of latanoprostene bunod (LBN) ophthalmic solution 0.024% every evening (qpm) with timolol maleate...” PMID 26875002 ↗ Feb 2016 “PURPOSE: To compare the intraocular pressure (IOP)-lowering effect of latanoprostene bunod (LBN) 0.024% with timolol maleate 0.5% in subjects with open-angle glaucoma (OAG) or...” PMID 27210275 ↗ May 2016 “This study will examine the efficacy and safety of topically applied beta-antagonist Timoptic-XE® (timolol maleate ophthalmic gel forming solution) in subjects with DFUs.” PMID 32513257 ↗ Jun 2020 “the alpha2-adrenergic agonist brimonidine tartrate 0.2% to the beta-adrenergic antagonist timolol maleate 0.5% in preserving visual function in low-pressure glaucoma.” PMID 21257146 ↗ Jan 2011 “compared three administrations of 10- or 15-µg bimatoprost implant (day 1, weeks 16 and 32) with twice-daily topical timolol maleate 0.5%.” PMID 35643967 ↗ May 2022 “Sham surgery plus postoperative active-comparator eye drops (timolol maleate ophthalmic solution, 0.5%).” NCT03519386 ↗ “Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops” NCT03966560 ↗ “One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks” NCT01026831 ↗ “Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution)” NCT00471068 ↗ “Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension” NCT02325518 ↗ “timolol maleate ophthalmic gel-forming solution (TGFS) (0.25% and 0.5%)” PMID 19683191 ↗ Aug 2009 “Preservative-free timolol maleate (0.5%) ophthalmic solution” NCT01254604 ↗ “Timolol Maleate (0.5%) ophthalmic solution dosed twice daily” NCT01845038 ↗ “Timolol maleate 0.5% ophthalmic solution will be used.” NCT01873131 ↗ “Cosopt (dorzolamide hydrochloride and timolol maleate)” NCT00440336 ↗ “Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)” NCT06030193 ↗ “Timolol Maleate ophthalmic solution, 0.5%” NCT03868124 ↗ “Timolol maleate ophthalmic solution, 0.5%” NCT00465803 ↗ “Timolol Maleate Ophthalmic Solution, 0.5%” NCT06120842 ↗ “Timolol Maleate Ophthalmic Solution 0.5%” NCT00293787 ↗ “Timolol maleate 0.5% ophthalmic solution” NCT05165082 ↗ “topical Timolol maleate 0.5% eye drops” NCT04288700 ↗ “timolol maleate 0.5% drops” NCT00800423 ↗ “Timolol Maleate Solution” NCT01279083 ↗ NCT01978600 ↗ NCT01518244 ↗ NCT02246764 ↗ NCT02207491 ↗ NCT00879099 ↗ NCT01978015 ↗ NCT04830397 ↗ NCT03931317 ↗ NCT06677853 ↗ NCT00815373 ↗ NCT00519753 ↗ NCT03691649 ↗ NCT01752049 ↗ NCT03691662 ↗ NCT00273481 ↗ NCT00287521 ↗ NCT02250612 ↗ NCT03323164 ↗ NCT06824948 ↗ NCT01434849 ↗ NCT01707381 ↗
Known as	Timolol maleate 0.5%	“Timolol maleate 0.5% topical solution” NCT02731287 ↗
Known as	Timolol maleate component of combigan	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Timolol maleate component of cosopt	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Timolol maleate component of duotrav	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Timolol maleate component of ganfort	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Timolol maleate component of xalacom	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Timolol maleate, s-enantiomer	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Timolol Maleate/Sorbitol Complex	“Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical)” NCT00698945 ↗
Known as	Timololi maleas	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Timoptic	“Randomized, Multicenter, Open-label, Parallel Group Study to Evaluate Efficacy and Safety of Combigan(Brimonidine/Timolol) and 0.5% Timoptic(Timolol) Ophthalmic Solutions in...” NCT01446497 ↗ 4 “Timolol (0.5%, non-selective beta-blocker, Timoptic®” NCT00275756 ↗ “Timolol 0.5% Ophthalmic Solution (Timoptic)” NCT00763061 ↗ NCT01520116 ↗ NCT00368602 ↗
Known as	Timoptic in ocudose	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	Timoptic-XE	“Timoptic-XE” NCT03282981 ↗
Known as	Timoptol	“carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)” NCT00972426 ↗ 1 “Timoptol 0,5%” NCT01887223 ↗
Known as	Tiopex	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Known as	TM gel	“The goal of this clinical trial is to evaluate the safety and efficacy of timolol maleate (TM) gel in subjects with superficial infantile hemangioma (IH) in the proliferative phase.” NCT06677853 ↗
Known as	Topical Timolol	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06140186 ↗
Known as	WP-934	ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗
Action	Inhibit	“Beta-1 adrenergic receptor antagonist” CHEMBL499 ↗ 2 “Beta-2 adrenergic receptor antagonist” CHEMBL499 ↗ “non-selective beta-blocker” NCT00275756 ↗
Modality	Other / unclassified	“Timolol, a beta blocker” NCT02754596 ↗
Route	Topical	“timolol maleate ophthalmic gel-forming solution” PMID 19683191 ↗ Aug 2009
Target	ADRB1	“Beta-1 adrenergic receptor antagonist” CHEMBL499 ↗
Target	ADRB2	“Beta-2 adrenergic receptor antagonist” CHEMBL499 ↗